Clinical trials
Amyloidosis clinical trials
Below are recruiting amyloidosis clinical trials, each written for real people, not researchers. We’re tracking 150 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06894290Recruiting
International heart disease registry for amyloidosis
This study collects information from people with a specific type of heart disease called cardiac amyloidosis (AL or ATTR type). By joining a registry, you help doctors learn more about these conditions and how to better treat them.
BrugesAges 18 years+ - NCT07266116RecruitingPhase 1/Phase 2
TQB2934 injection for light chain amyloidosis
This trial tests a new injectable drug called TQB2934 for people with systemic light chain amyloidosis. It aims to see if the drug is safe and effective for those whose disease has come back or gotten worse after previous treatment.
Beijing, Beijing MunicipalityAges 18–80 - NCT07250269RecruitingPhase 1
CAR-T therapy for AL amyloidosis
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
BeijingAges 18 years+ - NCT06907836Recruiting
Transthyretin cardiac amyloidosis in internal medicine
This study looks back at medical records of patients who were diagnosed with transthyretin cardiac amyloidosis (a type of protein buildup in the heart) while hospitalized in internal medicine at Strasbourg University Hospitals between 2013 and 2023. It aims to describe their health journey and outcomes.
StrasbourgAges 18 years+ - NCT07224672RecruitingPhase 2
Study of a drug combo for newly diagnosed AL amyloidosis
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
Rochester, MinnesotaAges 18 years+ - NCT07223203RecruitingPhase 3
Study of nucresiran for hereditary nerve condition (hATTR-PN)
This trial tests a new medicine called nucresiran for people with a rare genetic nerve condition (hATTR-PN). The goal is to see if it can slow down or improve nerve damage.
Aurora, ColoradoAges 18–85 - NCT06907186Recruiting
Psychological support program for amyloidosis patients and families
This study tests a structured psychological support program for people with hereditary transthyretin amyloidosis (ATTRv) with heart involvement, their caregivers, and those who carry the gene but have no symptoms yet. The goal is to see if the program is practical and well-accepted.
PaviaAges 18 years+ - NCT07216469Recruiting
Heart Stiffness in Amyloidosis: A Study Using MRI
This study uses a special MRI scan to measure how stiff the heart muscle is in people with cardiac amyloidosis. The goal is to better understand the condition and potentially guide future treatments.
Rochester, MinnesotaAges 20 years+ - NCT07218705Recruiting
MCG scan study for cardiac amyloidosis
This study uses a new type of heart scan (MCG) to help understand cardiac amyloidosis. It may help doctors learn more about the condition without needing invasive tests.
Rochester, MinnesotaAges 18 years+ - NCT07215494Recruiting
AL Amyloidosis: Testing for Hidden Disease After Transplant
This study looks for 'minimal residual disease' (tiny traces of amyloid after treatment) in people with AL amyloidosis who have had a stem cell transplant. It helps doctors understand if more treatment is needed.
Beijing, Beijing MunicipalityAges 18–70 - NCT06699394Recruiting
Teclistamab for AL amyloidosis after standard therapy
This trial tests an experimental drug, teclistamab, for people with a type of amyloidosis (AL) that has not improved with standard treatments. It aims to see if teclistamab can help when other treatments have not worked.
Beijing, Beijing MunicipalityAges Any age - NCT07151690RecruitingPhase 2
BCMA/CD3 bispecific antibody for newly diagnosed AL amyloidosis
This trial tests a new bispecific antibody treatment for people newly diagnosed with AL amyloidosis. The drug targets BCMA on myeloma cells and CD3 on immune cells to help your body fight the disease.
TianjinAges 18 years+ - NCT07154381Recruiting
Hybrid PET/MRI for heart amyloidosis imaging
This study uses a hybrid PET/MRI scanner to take detailed images of the heart in people with amyloidosis. The goal is to see how well this scan shows the buildup of amyloid protein, which could help doctors better diagnose and manage the condition.
Essen, North Rhine-WestphaliaAges 40 years+ - NCT07130565Recruiting
Pan-Amyloid PET/CT Scan for Amyloid Heart Disease
This trial is testing a special PET/CT scan (Pan-Amyloid) that finds abnormal protein deposits (amyloid) in the heart and body. It is for people who have or may have cardiac amyloidosis and are already planning to get this scan.
Hefei, AnhuiAges 18–80 - NCT07124377Recruiting
Study of hereditary ATTR amyloidosis symptoms
This study looks at how a specific genetic change (Val50Met) affects people with hereditary ATTR amyloidosis. It may help doctors better understand the condition and its symptoms.
Charata, Chaco ProvinceAges 20 years+ - NCT07110844RecruitingPhase 2
Teclistamab with Daratumumab for Newly Diagnosed AL Amyloidosis
This trial tests a combination of two drugs (teclistamab and daratumumab) for people with AL amyloidosis who have not had prior treatment. The goal is to see if this combination can safely and effectively reduce the abnormal protein deposits in organs.
Boston, MassachusettsAges 18–100 - NCT06971380RecruitingPhase 2
CAR-T therapy for multiple myeloma and amyloidosis
This trial tests a new CAR-T cell treatment (HBI0101) for people with multiple myeloma or light-chain amyloidosis that has come back or stopped responding to other treatments. The therapy uses your own immune cells to fight cancer, and the goal is to see if it can help control the disease.
JerusalemAges 18 years+ - NCT07079423RecruitingPhase 2
Teclistamab for new advanced AL amyloidosis
This trial tests a new drug called teclistamab for people newly diagnosed with advanced (stage IIIB) AL amyloidosis, a condition where abnormal proteins build up and damage organs. The goal is to see if teclistamab can help control the disease.
BeijingAges 18 years+ - NCT06935162RecruitingPhase 2
Teclistamab for previously treated AL amyloidosis
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07052903RecruitingPhase 3
RNA therapy for ATTR amyloidosis with heart involvement
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
La Jolla, CaliforniaAges 18–85 - NCT07039578RecruitingPhase 2
Study of CM336 for light-chain amyloidosis
This trial tests a new injection called CM336 for people with light-chain amyloidosis that has come back or not responded to other treatments. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07033715Recruiting
Exercise for hereditary ATTR amyloidosis in Portugal
This trial tests whether a structured exercise program can help people with hereditary ATTR amyloidosis (a condition that affects nerves and organs). It is for people in Portugal with early to moderate disease who can safely exercise.
Maia, Porto DistrictAges 18 years+ - NCT06998875RecruitingPhase 4
Study of avastin and tofacitinib for skin amyloidosis
This trial looks at people with primary cutaneous amyloidosis who have been treated with Avastin Capsules or Tofacitinib Citrate. It aims to track how well these medications work and if they are safe over time.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06974877RecruitingPhase 1
PET/CT Imaging for Amyloid in CAPS on Anakinra
This trial uses a special PET/CT scan to see if a radioactive tracer can measure changes in amyloid buildup in people with CAPS who have developed a skin reaction to anakinra. It may help doctors understand how the disease is affecting your organs.
Bethesda, MarylandAges 18–120
Hear when a new Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for amyloidosis?
- Yes. Clin2 currently lists 150 recruiting amyloidosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a amyloidosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a amyloidosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.